Fulgent Genetics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $90.4 million, up 8% year over year and 6% sequentially; the increase primarily reflected integration of Bako Diagnostics and StrataDX.
- Precision Diagnostics revenue was $41.8 million, down 18% year over year and up 1% sequentially; anatomic pathology revenue was $40.9 million, up 57% year over year and 9% sequentially; biopharma services revenue was $7.7 million, up 5% year over year and 19% sequentially.
- GAAP gross margin was 35.3% and non-GAAP gross margin was 36.3%. GAAP operating expenses were $54.5 million and non-GAAP operating expenses were $44.8 million.
- GAAP loss was $13.2 million, or $0.48 per share based on 27.7 million weighted average diluted shares outstanding. Non-GAAP loss was approximately $2.4 million, or $0.09 per share; adjusted EBITDA was a loss of approximately $7.5 million.
- The company ended the quarter with approximately $652.4 million in cash, cash equivalents, restricted cash, and marketable securities, following a $112.3 million federal tax refund and related interest.
- Fulgent repurchased just over 15,000 shares in the 3rd quarter. Since the stock repurchase program began in March 2022, over 7.5 million shares have been repurchased, with approximately 75.6 million currently remaining available for future purchases.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, ladies and gentlemen, and welcome to the Fulgent Genetics Q3 2026 conference call and webcast call. At this time, all lines are in listen-only mode, and following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded on Thursday, November 5, 2026. I will now turn the call over to Lauren Sloane.
Please go ahead. Good afternoon, and welcome to Fulgent's third quarter 2026 financial results conference call.
On the call are Ming Hsieh, Chief Executive Officer, Paul Kim, Chief Financial Officer, and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing the financial results is available on the investor relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the investor relations section of the company's website. Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on current views, expectations, and assumptions, which may prove to be incorrect. As a result, matters discussed in any forward-looking statements are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ from those described in the forward-looking statements.
The company assumes no obligation to update any of the forward-looking statements it may make today to reflect actual results or changes in expectations. Listeners should not rely on any forward-looking statements as predictions of future events and should listen to management's remarks today with the understanding that actual events, including the company's actual future results, may be materially different from what is described in or implied by these forward-looking statements. Please review the more detailed discussions related to these forward-looking statements, including the discussions of some of the risk factors that may cause results to differ from those described in the forward-looking statements contained in the company's filings with the Securities and Exchange Commission, including the previously filed 10-K for the year ended December 31, 2025, and subsequently filed reports, which are available on the company's investor relations website.
Management's remarks, including discussions of non-GAAP profit, loss, operating expense, margin, earnings, and earnings per share, and Adjusted EBITDA, contain financial measures not prepared in accordance with accounting principles generally accepted in the U.S., or GAAP. Management has presented these non-GAAP financial measures because it believes they may be useful for investors for various reasons, but these measures should not be viewed as a substitute for or superior to the company's financial results in accordance with GAAP.
Please see the company's press release discussing its financial results for the third quarter of 2026 for more information, including the description of how the company calculates non-GAAP income and loss, non-GAAP earnings and loss per share, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating profit and loss and margin, and Adjusted EBITDA, and a reconciliation of these financial measures to income and loss, earnings loss per share, and operating margin, the most directly comparable GAAP financial measures. The company does not provide reconciliation of forward-looking non-GAAP measures to the most directly comparable GAAP measures because the information necessary to calculate such reconciliations, including equity-based compensation, tax effects, acquisition-related items, and potential impairments, any of which may be material, is unavailable on a forward-looking basis without unreasonable effort, and the probable significance of those items cannot be predicted. With that, I'd now like to turn the call over to Ming.
Please go ahead. Thank you, Lauren.
I will start with some comments on our two business lines. Brandon will reveal our product and go-to-market updates for our laboratory service business, and Paul will conclude with the financials and outlook before we take your questions. I am pleased with the momentum in our therapeutic development business as we progress on our clinical pipeline. We are seeing encouraging clinical data from our proprietary nano drug delivery platform, which powers both FID-007 and FID-022. Let me share the recent updates from FID-007 and then share the progress we have made with FID-022. As a reminder, Fulgent has taken a different approach with FID-007. FID-007 is a nano-encapsulated paclitaxel developed under Fulgent's CleanChemo platform. The platform is designed to reduce toxicity typically associated with conventional chemotherapy while maintaining or improving efficacy, a profile Fulgent believes is preferable in combination oncology regimens.
Starting with FID-007, with the majority of phase II complete, we held the end of a phase II meeting with the FDA in August. We look forward to sharing more with you later this year. Our phase III study is in preparation. We are encouraged by our clinical trial progress achieved so far and believe the interim phase III registration trial is an important step toward the potential commercialization of FID-007 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma patients, who currently have very few effective treatment options. We continue to approach conversations with partners who bring both resource and strategies alignment. In the third quarter, we were pleased with the momentum of our second clinical candidate, FID-022.
With the phase I dosing escalation at the fifth dosing level ongoing, we expect to determine the maximum tolerated dose level in the first half of next year. FID-022 is a nano-encapsulated SN-38 for treatment of solid tumors, including potentially colon, pancreatic, ovarian, and bile duct cancers. Please note, both FID-007 and FID-022 are derived from the same proprietary CleanChemo delivery platform, patented and fully owned by Fulgent. Similar to FID-007, FID-022 can also be used in various oncology drug combinations. In conclusion, we believe our common platform strategy is making meaningful progress. We are seeing greater potential in commercializing FID-007 and FID-022 to drive a large and growing market. In laboratory services business, we continue to see our AI and digital pathology solution work at an accelerated pace and are continuing to expand our AI portfolios.
We are pleased with the progress we have made to address billing and revenue cycle management delays, which continue to affect our third quarter results and our team's ability to work effectively to deliver the improvements to our collection rates. I would like to thank our employees, partners, and stakeholders for your hard work and loyalty. I will now turn over the call to Brandon Perthuis, our Chief Commercial Officer, to talk more about our laboratory services business.
Brandon? Thank you, Ming. We ended the quarter at $90.4 million, an increase of 8% year-over-year and 6% sequentially.
We continued integration efforts for Bako and StrataDx during the third quarter, which contributed to the overall performance. Breaking it down further, Precision Diagnostics ended at $41.8 million, a decrease of 18% year-over-year, but an increase of 1% sequentially. Anatomic Pathology came in at $40.9 million, an increase of 57% year-over-year and 9% sequentially. BioPharma Services ended the quarter at $7.7 million, an increase of 5% year-over-year and 19% sequentially. Last quarter, we discussed managing the final phase of the transition of our billing and revenue cycle management system. We originally undertook this transition to achieve greater consistency across our operations and to drive long-term efficiency.
While this transition continued to have a negative impact on the third quarter, we are pleased to announce we have made significant progress and have seen a positive sequential trend in reimbursement, which has contributed to improvements in our total revenue and gross margins as compared to the second quarter. While there is still additional effort needed to finalize the remaining customizations, and we cannot predict more precise timing for future improvements, we believe we have a clear line of sight into what is needed to return to historical collection rates. We continue to monitor developments related to PAMA and any potential changes to the Clinical Laboratory Fee Schedule. Based on what we know today, we expect the impact to our business to be minimal. Our primary CPT codes have limited exposure to the reimbursement reductions currently contemplated under PAMA.
As a result, we do not currently view PAMA as a material headwind to our revenue or earnings outlook. We will remain engaged with the evolving reimbursement landscape, but at this point, we feel comfortable with our positioning. We continue to make significant progress integrating artificial intelligence into our pathology workflow. During the third quarter, our AI platform analyzed approximately 255,000 slide images, representing a 23% increase from the second quarter. Importantly, as utilization has scaled, the technical reliability of the platform has improved substantially, with failed analysis declining to just 0.01% during the quarter. We now have four AI modules in production, with our prostate cancer detection and grading module undergoing pathologist evaluation. During the quarter, we also transitioned our production environment to a new AI analysis platform designed to improve speed, reliability, and scalability.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
